Arcellx rises as FDA lifts partial clinical hold on cancer therapy study

Arcellx

15/08/2023 16:43

** Shares of therapy developer Arcellx Inc  ACLX.O  rise
6.39% to $35.83
    ** Co said U.S. FDA has lifted the partial clinical hold
placed on its experimental therapy CART-ddBCMA which is in
mid-stage trial 
    ** It is being studied as a treatment of patients with a
type of blood cancer known as multiple myeloma
    ** During the partial clinical hold, FDA approved dosing of
all 17 patients who had been enrolled but not yet dosed prior to
the hold - ACLX
     ** Continues to expect commercial launch of CART-ddBCMA 
which is being co-developed with Gilead's  GILD.O  unit Kite to
be in 2026
    ** Stock up ~16% YTD

 (Reporting by Sriparna Roy in Bengaluru)
 ((Sriparna.Roy@thomsonreuters.com;))